Federica Moschella

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

E. Coli cytotoxic necrotizing factor-1 promotes colorectal carcinogenesis by causing oxidative stress, DNA damage and intestinal permeability alteration.

E. Coli cytotoxic necrotizing factor-1 promotes colorectal carcinogenesis by causing oxidative stress, DNA damage and intestinal permeability alteration.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 23, 2024

Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.

Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.

Journal: Frontiers in oncology

Published: January 16, 2023

Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells.

Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells.

Journal: Molecules (Basel, Switzerland)

Published: August 31, 2022

Nicotinamide inhibits melanoma in vitro and in vivo.

Nicotinamide inhibits melanoma in vitro and in vivo.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 30, 2020

Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy.

Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy.

Journal: Frontiers in immunology

Published: July 13, 2020

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study.

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study.

Journal: Frontiers in oncology

Published: October 16, 2019

Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

Journal: Cancer immunology research

Published: November 24, 2017

The added value of type I interferons to cytotoxic treatments of cancer.

The added value of type I interferons to cytotoxic treatments of cancer.

Journal: Cytokine & growth factor reviews

Published: May 31, 2017

Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide.

Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide.

Journal: International journal of cancer

Published: March 29, 2017

Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.

Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.

Journal: Cytokine & growth factor reviews

Published: December 18, 2014

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.

Journal: Journal of translational medicine

Published: November 18, 2014

Exploiting dendritic cells in the development of cancer vaccines.

Exploiting dendritic cells in the development of cancer vaccines.

Journal: Expert review of vaccines

Published: October 05, 2013

Showing 1-12 of 16

Last Updated: 09/26/2026